A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline

Bedaquiline is a new ATP synthesis inhibitor developed as an anti-tuberculosis agent. It has resistance-associated variants (RAV), regardless of preceding bedaquiline exposure. Herein, we describe the case of a patient with multidrug-resistant tuberculosis (MDR-TB) who had no history of bedaquiline...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2022-08, Vol.28 (8), p.1193-1197
Hauptverfasser:	Kobayashi, Masahiro, Motoki, Yuya, Yamagishi, Tetuya, Hirano, Hitomi, Nonaka, Mizu, Aono, Akio, Mitarai, Satoshi, Saito, Takefumi
Format:	Artikel
Sprache:	eng
Schlagworte:	Bedaquiline Multidrug-resistant tuberculosis Mycobacterium tuberculosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!